• 1
    Koller M, Schoch U, Buchmann P, et al. Low molecular weight heparin (KABI 2165) as thromboprophylaxis in elective visceral surgery. A randomized, double-blind study versus unfractionated heparin. Thromb Haemost. 1986;56:243246.
  • 2
    Gomez-Outes A, Lecumberri R, Lafuente-Guijosa A, et al. Correlation between thrombus regression and recurrent venous thromboembolism. Examining venographic and clinical effects of low-molecular-weight heparins: a meta-analysis. J Thromb Haemost. 2004;2:15811587.
  • 3
    Luomanmaki K, Grankvist S, Hallert C, et al. A multicentre comparison of once-daily subcutaneous dalteparin (low molecular weight heparin) and continuous intravenous heparin in the treatment of deep vein thrombosis. J Intern Med. 1996;240:8592.
  • 4
    Grebe S, Jacobs C, Kietzmann M, Mischke R. [Phamacokinetics of low-molecular-weight heparins Fragmin D in dogs]. Berl Munch Tierarztl Wochenschr. 2000;113:103107.
  • 5
    Mischke R, Fehr M, Nolte I. Efficacy of low molecular weight heparin in a canine model of thromboplastin-induced acute disseminated intravascular coagulation. Res Vet Sci. 2005;79:6976.
  • 6
    Morris TA, Marsh JJ, Konopka R, Pedersen CA, Chiles PG. Anti-thrombotic efficacies of enoxaparin, dalteparin, and unfractionated heparin in venous thrombo-embolism. Thromb Res. 2000;100:185194.
  • 7
    Szucs G, Miko I, Ajzner E, et al. Efficacy of prevention of thromboembolic complications with LMW-heparin in experiment. Acta Chir Hung. 1997;36:356358.
  • 8
    Leizorovicz A, Bara L, Samama MM, Haugh MC. Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage. Haemostasis. 1993;23 (Suppl 1):8998.
  • 9
    Bara L, Planes A, Samama MM. Occurrence of thrombosis and haemorrhage, relationship with anti-Xa, anti-IIa activities, and D-dimer plasma levels in patients receiving a low molecular weight heparin, enoxaparin or tinzaparin, to prevent deep vein thrombosis after hip surgery. Br J Haematol. 1999;104:230240.
  • 10
    Hakki SI, Fareed J, Hoppensteadt DA, et al. Plasma tissue factor pathway inhibitor levels as a marker for postoperative bleeding after enoxaparin use in deep vein thrombosis prophylaxis in orthopedics and general surgery. Clin Appl Thromb Hemost. 2001;7:6571.
  • 11
    Wiinberg B, Jensen AL, Rojkjaer R, et al. Validation of human recombinant tissue factor-activated thromboelastography on citrated whole blood from clinically healthy dogs. Vet Clin Pathol. 2005;34:389393.
  • 12
    Srinivasa V, Gilbertson LI, Bhavani-Shankar K. Thromboelastography: where is it and where is it heading? Int Anesthesiol Clin. 2001;39:3549.
  • 13
    Harding SA, Mallett SV, Peachey TD, Cox DJ. Use of heparinase modified thrombelastography in liver transplantation. Br J Anaesth. 1997;78:175179.
  • 14
    Royston D, Von Kier S. Reduced haemostatic factor transfusion using heparinase-modified thrombelastography during cardiopulmonary bypass. Br J Anaesth. 2001;86:575578.
  • 15
    Shore-Lesserson L. Evidence based coagulation monitors: heparin monitoring, thromboelastography, and platelet function. Semin Cardiothorac Vasc Anesth. 2005;9:4152.
  • 16
    Shinoda T, Arakura H, Katakura M, Shirota T, Nakagawa S. Usefulness of thromboelastography for dosage monitoring of low molecular weight heparin and unfractionated heparin during hemodialysis. Artificial Organs. 1999;14:413415.
  • 17
    Fenyvesi T, Jorg I, Harenberg J. Effect of phenprocoumon on monitoring of lepirudin, argatroban, melagatran and unfractionated heparin with the PiCT method. Pathophysiol Haemost Thromb. 2002;32:174179.
  • 18
    Wiinberg B, Jensen AL, Kjelgaard-Hansen M, et al. Study on biological variation of haemostatic parameters in clinically healthy dogs. Vet J. 2007;174:6268.
  • 19
    Mischke R, Grebe S. The correlation between plasma anti-factor Xa activity and haemostatic tests in healthy dogs, following the administration of a low molecular weight heparin. Res Vet Sci. 2000;69:241247.
  • 20
    Mischke R, Grebe S, Jacobs C, Kietzmann M. Amidolytic heparin activity and values for several hemostatic variables after repeated subcutaneous administration of high doses of a low molecular weight heparin in healthy dogs. Am J Vet Res. 2001;62:595598.
  • 21
    Zmuda K, Neofotistos D, Ts'ao CH. Effects of unfractionated heparin, low-molecular-weight heparin, and heparinoid on thromboelastographic assay of blood coagulation. Am J Clin Pathol. 2000;113:725731.
  • 22
    Gerotziafas GT, Chakroun T, Samama MM, Elalamy I. In vitro comparison of the effect of fondaparinux and enoxaparin on whole blood tissue factor-triggered thromboelastography profile. Thromb Haemost. 2004;92:12961302.
  • 23
    Jessen LR, Wiinberg B, Kjelgaard-Hansen M, Kristensen AT. Dalteparin causes significant dose related changes in tissue factor and kaolin activated whole blood thromboelastography (TEG) parameters [abstract]. J Vet Intern Med. 2006;20:714.
  • 24
    White RH, Ginsberg JS. Low-molecular-weight heparins: are they all the same? Br J Haematol. 2003;121:1220.
  • 25
    Houbouyan L, Boutiere B, Contant G, et al. Validation protocol of analytical hemostasis systems: measurement of anti-Xa activity of low-molecular-weight heparins. Clin Chem. 1996;42:12231230.
  • 26
    Desjardins L, Bara L, Boutitie F, et al. Correlation of plasma coagulation parameters with thromboprophylaxis, patient characteristics, and outcome in the MEDENOX study. Arch Pathol Lab Med. 2004;128:519526.
  • 27
    Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb Haemost. 2002;87:163164.
  • 28
    Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood. 1991;78:23372343.